相关实验视频

Updated: Jul 1, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

在质瘤中,GINS2通过EGR1/ECT2轴调节temozolomide的化学敏感性

Hua He^1,2, Lu Liang^1,2, Shiyao Jiang^1,2

¹The Key Laboratory of Model Animal and Stem Cell Biology in Hunan Province, Hunan Normal University, Changsha, 410013, Hunan, China.

Cell death & disease

|March 12, 2024

概括

通过促进DNA修复,GINS2增强了质瘤细胞对temozolomide (TMZ) 的抵抗力. 用Palbociclib/BIX-02189针对GINS2提供了一个有前途的结合疗法来治疗质瘤.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

泰莫佐洛米德 (Temozolomide,简称TMZ) 是一种常见的大脑瘤结质瘤的初级治疗方法.
质瘤患者经常由于强大的DNA损伤反应 (DDR) 而经历治疗失败,导致低化学敏感性.
GINS2是一种DNA螺旋酶子单元,在癌症中受到上调,并与基因组不稳定性有关.

研究的目的:

为了研究GINS2在质瘤中对temozolomide耐药性的作用.
确定新的治疗目标和改善质瘤治疗结果的策略.

主要方法:

在TMZ治疗的质瘤细胞中分析GINS2表达.
研究GINS2在DNA损伤修复和细胞表型中的作用.
构建一个GINS2-EGR1-ECT2预后模型.
查抑制GINS2表达并增强TMZ疗效的药物.

主要成果:

在TMZ治疗时,GINS2的表达在质瘤细胞上升调节,并参与TMZ诱导的DDR.
通过调节EGR1mRNA稳定性,GINS2促进DNA损伤的修复,影响ECT2转录.
该GINS2-EGR1-ECT2模型准确预测患者的生存率.
确定Palbociclib/BIX-02189可以抑制GINS2表达,并与TMZ协同抑制质瘤细胞增殖.

结论:

通过调节DNA修复通路,GINS2在调节质瘤细胞对TMZ的化学敏感性方面发挥着至关重要的作用.
GINS2-EGR1-ECT2轴代表了一种影响质瘤进展和预后的新机制.
针对GINS2使用Palbociclib/BIX-02189等药物与TMZ结合,为质瘤提供了一个有前途的治疗策略.

更多相关视频

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...